Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Cynapsus Therapeutics Inc. $72.5 Million Initial Public Offering
Davis Polk advised the underwriters in connection with the $72.5 million U.S. initial public offering of 5,175,000 common…
Biotie Therapies Corp. Initial Public Offering
Davis Polk advised Biotie Therapies Corp. (“Biotie”) on its $56.7 million U.S. initial public offering of 3,806,047 American…
3SBio Inc. HK$5.5 Billion (US$711.6 Million) Initial Public Offering
Davis Polk advised the underwriters as joint global coordinators on the initial public offering and listing on the Main…
Bio-Reference Laboratories $1.47 billion acquisition by OPKO Health
Davis Polk is advising Bio-Reference Laboratories, Inc. in connection with its approximately $1.47 billion acquisition by…
Hologic, Inc. $2.5 Billion Senior Secured Credit Facilities Refinancing
Davis Polk advised the administrative agent in connection with the refinancing of Hologic, Inc.’s existing senior secured…
Davis Polk Advises Auris Medical Holding AG on Its Offering of Common Shares
Davis Polk advised Auris Medical Holding AG (“Auris Medical”) on its $25.1 million public offering of 5,275,000 of its…
Galapagos NV €278.7 Million Global Offering Of Ordinary Shares
Davis Polk advised the several underwriters, in connection with Galapagos NV’s global offering of 7,532,499 of its ordinary…
Anthem $1.25 Billion Equity Units Offering
Davis Polk advised the joint book-running managers in connection with a registered public offering by Anthem, Inc. of $1.25…
Laboratory Corporation of America Holdings $2.9 Billion Senior Notes Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters on a public offering by…
Warner Chilcott $8.5 billion acquisition by Actavis
Davis Polk is advising Warner Chilcott plc in connection with its approximately $8.5 billion acquisition by Actavis, Inc. in…